Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, ...

Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.25, a high estimate of $126.00, and a low estimate of $70.00. This current ...

BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

Sanofi SA (NASDAQ:SNY) and Johnson & Johnson (NYSE:JNJ) have discontinued the E.mbrace phase 3 study evaluating a vaccine candidate for extraintestinal pathogenic E. coli. The E.mbrace study is a ...

Also Read: Sanofi Genzyme Facility Draws FDA Criticism Over Alleged Quality Lapses An independent data monitoring committee (IDMC) conducted a scheduled review of the E.mbrace phase 3 study.

Genzyme has fallen foul of the UK pharma industry ... AstraZeneca has also been named in advertisements along with the Sanofi unit, following breaches of the Association of the British ...

L’Oreal OR0.83%increase; green up pointing triangle will sell part of its stake in Sanofi SAN-0.46%decrease; red down pointing triangle back to the French pharmaceutical company for 3 billion ...

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...

Sanofi is planning a $5.12bn share buyback programme in 2025. Image credit: Shutterstock / JHVEPhoto. Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L’Oréal, the first of ...